1Gharib MI,Burnett AK.Chemotherapy-induced cardiotoxicity:Current practice and prospects of prophylaxis[J].Eur J Heart Fail,2002,4(3):235～242.
2Janusz W,Ewa LN,Krzysztof LK,et al.Anthracycline-induced cardiotoxicity:clinical course,risk factors,pathogenesis,detection and prevention - review of the literature[J].Med Sci Monit,2000,6(2):411～420.
3Pai VB,Nahata MC.Cardiotoxicity of chemotherapeutic agents:Incidence,treatment and prevention[J].Drug Saf,2000,22 (4):263～302.
4Kremer LC,van Dalen EC,Offringa M,et al.Anthracycline-induced clinical heart failure in a cohort of 607 children:Long-term follow-up study[J].J Clin Oncol,2001,19(1):191～196.
5Herman EH,Zhang J,Lipshultz SE,et al.Correlation between serum levels of cardiac troponin and the severity of the chronic cardiomyopathy induced by doxorubicin[J].J Clin Oncol,1999,17(7):2 237～2 243.
6Meinardi MT,Van der Graaf WT,Van Veldhuisen DJ,et al.Detection of anthracycline-induced cardiotoxicity[J].Cancer Treat Rev,1999,25(4):237～247.
7Bertinchant JP,Polge A,Robert E,et al.Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats,and their relationship with echocardiographic and histological findings[J].Clin Chim Acta,2003,329(1～2):39～51.
8Lipshultz SE,Rifai N,Sallan SE,et al.Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury[J].Circulation,1997,96(8):2 641～2 648.
9Lipshultz S,Sallan S,Dalton V,et al.Elevated serum cardiac troponin-T as a marker for active cardiac injury during therapy for childhood acute lymphoblastic leukemia(ALL)[J].Proc Am Soc Clin Oncol,1999,18():568a.
10Sandri MT,Cardinale D,Zorzino L,et al.Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy[J].Clin Chem,2003,49(2):248～252.
